Cargando…
Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
S-217622 (Ensitrelvir) is a reversible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3-chymotrypsin-like protease (3CL(pro)) inhibitor which obtained emergency regulatory approval in Japan for the treatment of SARS-CoV-2 infection on Nov 22, 2022. Herein, analogs of S-271622 with deut...
Autores principales: | Yang, Yujian, Cao, Liu, Yan, Ming, Zhou, Jun, Yang, Sidi, Xu, Tiefeng, Huang, Siyao, Li, Kun, Zhou, Qifan, Li, Guanguan, Zhu, Yujun, Cong, Feng, Zhang, Hongmin, Guo, Deyin, Li, Yingjun, Zhang, Xumu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043954/ https://www.ncbi.nlm.nih.gov/pubmed/36997073 http://dx.doi.org/10.1016/j.antiviral.2023.105586 |
Ejemplares similares
-
Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside
por: Zhou, Qifan, et al.
Publicado: (2023) -
Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
por: Hu, Wei, et al.
Publicado: (2022) -
Novel Investigational
Anti-SARS-CoV-2 Agent
Ensitrelvir “S-217622”: A Very Promising Potential Universal
Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus
Species
por: Eltayb, Wafa A., et al.
Publicado: (2023) -
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
por: Cao, Liu, et al.
Publicado: (2022) -
Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses
por: Zhou, Qifan, et al.
Publicado: (2023)